OncologyPharmacy.Org

Your source for clear summaries and the latest oncology research. Empowering patients and professionals with accurate insight.

[OncologyPharmacy.Org @OncPharmOrg]

T-DXd Shows Promising Results for HER2+ Breast Cancer with Brain Metastases

#BreastCancer, #CentralNervousSystemCancer, #trastuzumabderuxtecan, #T-DXd
https://t.co/AgcGPKGItH

[OncologyPharmacy.Org @OncPharmOrg]

ADT and Heart Failure: New Study Reveals Increased Risk for Prostate Cancer Patients

#ProstateCancer, #AndrogenDeprivationTherapy
https://t.co/db3xWUdwjZ

[OncologyPharmacy.Org @OncPharmOrg]

Valemetostat Shows Promise in Treating Relapsed/Refractory Peripheral T-Cell Lymphoma

#TCellLymphomas, #valemetostat
https://t.co/ChNk6b79CJ

[OncologyPharmacy.Org @OncPharmOrg]

Novel Neoadjuvant Chemoradiation Approach Shows Promise for High-Risk Prostate Cancer

#ProstateCancer, #docetaxel
https://t.co/yQEb6ppzsK

[OncologyPharmacy.Org @OncPharmOrg]

Long-Term Study Confirms T-DM1's Superiority in HER2+ Breast Cancer Treatment

#BreastCancer, #trastuzumabemtansine, #trastuzumab
https://t.co/FKrdU1bGRB

[OncologyPharmacy.Org @OncPharmOrg]

PD-L1 Expression Predicts Immunotherapy Benefit in Advanced Gastroesophageal Cancer

#GastricCancer, #EsophagealCancers, #Anti-PD-1antibodies
https://t.co/oEYNeEw0Bh

[OncologyPharmacy.Org @OncPharmOrg]

ASC2ESCALATE: Exploring Asciminib's Potential in Early-Stage CML Treatment

#ChronicMyeloidLeukemia, #asciminib, #imatinib, #nilotinib, #bosutinib
https://t.co/PjD1uArZ0G

[OncologyPharmacy.Org @OncPharmOrg]

Neoadjuvant Endocrine Therapy Reduces Mastectomy Rates in Early Breast Cancer

#BreastCancer, #Aromataseinhibitors, #Selectiveestrogenreceptormodulators, #Selectiveestrogenreceptordownregulators
https://t.co/OSmDCZbc2s

[OncologyPharmacy.Org @OncPharmOrg]

Acupressure: A Promising Complementary Therapy for Chemotherapy-Induced Nausea in Breast Cancer

#BreastCancer, #SupportiveCare, #Antiemetics
https://t.co/2mH6AWJk0n

[OncologyPharmacy.Org @OncPharmOrg]

Pembrolizumab Shows Promise in Advanced Merkel Cell Carcinoma: KEYNOTE-913 Results

#SkinCancer, #pembrolizumab
https://t.co/aAw0sDNFRV

[OncologyPharmacy.Org @OncPharmOrg]

Capmatinib Shines in METex14 NSCLC: GEOMETRY mono-1 Trial Unveils Promising Results

#Non-SmallCellLungCancer, #capmatinib
https://t.co/TuwUP2V6ZG

[OncologyPharmacy.Org @OncPharmOrg]

Immunotherapy Breakthrough: Pembrolizumab Boosts Survival in Early-Stage Lung Cancer

#Non-SmallCellLungCancer, #pembrolizumab, #cisplatin
https://t.co/5PloMvMvs7

[OncologyPharmacy.Org @OncPharmOrg]

Immunotherapy Breakthrough: Pembrolizumab Boosts Survival in Advanced Cervical Cancer

#CervicalCancer, #GynecologicCancer, #pembrolizumab, #cisplatin
https://t.co/QEuvSZtx2L

[OncologyPharmacy.Org @OncPharmOrg]

7-Year Follow-Up: Pembrolizumab Shines in High-Risk Melanoma

#SkinCancer, #pembrolizumab, #placebo
https://t.co/3IWizQkaNc

[OncologyPharmacy.Org @OncPharmOrg]

New Analysis Supports Flexible Dosing Options for CML Drug Asciminib

#ChronicMyeloidLeukemia, #asciminib
https://t.co/Ih8iGAlCtH

[OncologyPharmacy.Org @OncPharmOrg]

Promising Brain Breakthrough: T-DXd Shows Hope for HER2-Low Breast Cancer with Brain Metastases

#BreastCancer, #CentralNervousSystemCancers, #trastuzumabderuxtecan
https://t.co/u2TKWLpmrE

[OncologyPharmacy.Org @OncPharmOrg]

Rucaparib's Promise: New Hope for Recurrent Ovarian Cancer Patients

#GynecologicCancers, #rucaparib
https://t.co/pL8FxEc9h2

[OncologyPharmacy.Org @OncPharmOrg]

Dual Checkpoint Inhibition Shows Promise in Rare Desmoid Tumors

#Sarcomas, #ipilimumab, #nivolumab
https://t.co/UvmKrztTm7

[OncologyPharmacy.Org @OncPharmOrg]

Weekly Cisplatin: A Kidney-Friendly Approach for Head and Neck Cancer Treatment

#HeadNeckCancer, #cisplatin
https://t.co/9BnYj0VOP6

[OncologyPharmacy.Org @OncPharmOrg]

Immunotherapy Rechallenge Falls Short in Advanced Kidney Cancer Trial

#KidneyCancer, #tivozanib, #nivolumab
https://t.co/w5xkMM33cy